105 related articles for article (PubMed ID: 14621863)
1. FK506 and rapamycin: differential sensitivity of human, baboon, cynomolgus monkey, dog and pig lymphocytes.
Metcalfe S; Svvennsen R; Calne RY
Transpl Int; 1992; 5 Suppl 1():S514-5. PubMed ID: 14621863
[TBL] [Abstract][Full Text] [Related]
2. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis.
Koenen HJ; Michielsen EC; Verstappen J; Fasse E; Joosten I
Transplantation; 2003 May; 75(9):1581-90. PubMed ID: 12792519
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells.
Cho CS; Chang Z; Elkahwaji J; Scheunemann TL; Manthei ER; Colburn M; Knechtle SJ; Hamawy MM
Int Immunol; 2003 Nov; 15(11):1369-78. PubMed ID: 14565935
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressants FK506 and rapamycin have different effects on the biosynthesis of cytoplasmic actin during the early period of T cell activation.
Miyamoto S; Safer B
Biochem J; 1999 Dec; 344 Pt 3(Pt 3):803-12. PubMed ID: 10585867
[TBL] [Abstract][Full Text] [Related]
5. The effects of rapamycin in murine peripheral nerve isografts and allografts.
Myckatyn TM; Ellis RA; Grand AG; Sen SK; Lowe JB; Hunter DA; Mackinnon SE
Plast Reconstr Surg; 2002 Jun; 109(7):2405-17. PubMed ID: 12045568
[TBL] [Abstract][Full Text] [Related]
6. Skin graft of double transgenic pigs of N-acetylglucosaminyltransferase III (GnT-III) and DAF (CD55) genes survived in cynomolgus monkey for 31 days.
Fujita T; Miyagawa S; Ezoe K; Saito T; Sato N; Takahagi Y; Murakami H; Matsunami K; Shirakura R; Taniguchi N
Transpl Immunol; 2004 Dec; 13(4):259-64. PubMed ID: 15589738
[TBL] [Abstract][Full Text] [Related]
7. Ex-vivo expanded baboon CD4+ CD25 Hi Treg cells suppress baboon anti-pig T and B cell immune response.
Singh AK; Seavey CN; Horvath KA; Mohiuddin MM
Xenotransplantation; 2012; 19(2):102-11. PubMed ID: 22497512
[TBL] [Abstract][Full Text] [Related]
8. FK506 and rapamycin modulate the functional activities of human peripheral blood eosinophils.
Hom JT; Estridge T
Clin Immunol Immunopathol; 1993 Sep; 68(3):293-300. PubMed ID: 7690315
[TBL] [Abstract][Full Text] [Related]
9. In vitro immunosuppressive activity of tacrolimus dihydrodiol precursors obtained by chemical oxidation and identification of a new metabolite of SDZ-RAD by electrospray and electrospray-linked scan mass spectrometry.
Lhoëst G; Hertsens R; Verbeeck RK; Maton N; Wallemacq P; Dehoux JP; Latinne D
J Mass Spectrom; 2001 Aug; 36(8):889-901. PubMed ID: 11523088
[TBL] [Abstract][Full Text] [Related]
10. The antimalarial action of FK506 and rapamycin: evidence for a direct effect on FK506-binding protein PfFKBP35.
Monaghan P; Leneghan DB; Shaw W; Bell A
Parasitology; 2017 Jun; 144(7):869-876. PubMed ID: 28274284
[TBL] [Abstract][Full Text] [Related]
11. Isolation from pig liver microsomes, identification by tandem mass spectrometry and in vitro immunosuppressive activity of an SDZ-RAD 17,18,19,20,21,22-tris-epoxide.
Lhoëst GJ; Gougnard TY; Verbeeck RK; Maton N; Dehoux JP; Wallemacq P; Schüler W; Latinne D
J Mass Spectrom; 2000 Mar; 35(3):454-60. PubMed ID: 10767777
[TBL] [Abstract][Full Text] [Related]
12. FK506 inhibits human lymphocyte migration and the production of lymphocyte chemotactic factors in liver allograft recipients.
Adams DH; Liu Q
Hepatology; 1996 Jun; 23(6):1476-83. PubMed ID: 8675167
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin--rather than FK506--might promote allograft tolerance induced by CD4+CD25+ regulatory T cells.
Du JF; Li SY; Yu B
Surgery; 2009 Sep; 146(3):526-7; author reply 527-8. PubMed ID: 19715817
[No Abstract] [Full Text] [Related]
14. Modes of action of FK506, cyclosporin A, and rapamycin.
Morris R
Transplant Proc; 1994 Dec; 26(6):3272-5. PubMed ID: 7527964
[No Abstract] [Full Text] [Related]
15. Treatment of normal skeletal muscle with FK506 or rapamycin results in halothane-induced muscle contracture.
Brooksbank RL; Badenhorst ME; Isaacs H; Savage N
Anesthesiology; 1998 Sep; 89(3):693-8. PubMed ID: 9743407
[TBL] [Abstract][Full Text] [Related]
16. Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A.
Keicho N; Kudoh S; Yotsumoto H; Akagawa KS
J Antibiot (Tokyo); 1993 Sep; 46(9):1406-13. PubMed ID: 7693639
[TBL] [Abstract][Full Text] [Related]
17. Human T cell responses to human and porcine endothelial cells are highly sensitive to cyclosporin A and FK506 in vitro.
Batten P; McCormack AM; Page CS; Yacoub MH; Rose ML
Transplantation; 1999 Nov; 68(10):1552-60. PubMed ID: 10589954
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of baboon lymphocytes to cyclosporin A and FK 506: relative resistance of alloactivated cells to CyA.
Stark JH; Smit JA; Gridelli B
Transpl Int; 1994 Aug; 7(5):372-8. PubMed ID: 7527639
[TBL] [Abstract][Full Text] [Related]
19. FK506 (tacrolimus) increases halothane-induced Ca2+ release from skeletal muscle sarcoplasmic reticulum.
Chini EN; Walker H
Anesthesiology; 2000 May; 92(5):1361-5. PubMed ID: 10781282
[TBL] [Abstract][Full Text] [Related]
20. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes.
Nagase K; Iwasaki K; Nozaki K; Noda K
J Pharm Pharmacol; 1994 Feb; 46(2):113-7. PubMed ID: 7517447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
